GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cyclerion Therapeutics
Shares of Cyclerion, a biopharmaceutical company focused on treating CNS diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs that modulate the nitric oxide signaling pathway for the treatment of central nervous system diseases. We've categorized it under the "Neurology" category. The chart below shows how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Cyclerion Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Cyclerion shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
CYCN - Daily change in the company's share price Cyclerion Therapeutics
For Cyclerion Therapeutics, Inc., a neuroscience company, daily price change is a measure of its enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system. Neuroscience biotechnology is a high-risk, high-potential industry. The chart below shows the average volatility in this segment, serving as a barometer for assessing CYCN stock price movements.
Daily change in the price of a broad market stock, index - GURU.Markets
Cyclerion Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cyclerion Therapeutics
For Cyclerion Therapeutics, its year-over-year performance is a story of its strategic pivot. Its 12-month market cap reflects its decision to focus on developing drugs for rare CNS diseases. Its valuation is a bet that this narrower, more focused approach will prove successful after previous setbacks.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech company, Cyclerion is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclerion Therapeutics, focused on treating diseases of the central nervous system, operates in one of the most complex areas of pharmaceuticals. Comparing its year-over-year market capitalization dynamics with the market reveals how investors assess the risks and potential breakthroughs in this field. Clinical trial news is the main driver of its shares.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cyclerion Therapeutics
Cyclerion is a clinical-stage biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its key drugs are binary events for its stock.
Monthly dynamics of market capitalization of the market segment - Neuro
Cyclerion Therapeutics is a biotech company developing drugs to treat serious diseases of the central nervous system. Its value, like many similar companies, is determined by progress in clinical trials. The neuroscience segment chart shows overall investor interest in this area, which provides a backdrop for assessing Cyclerion's risks and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclerion Therapeutics develops drugs to treat rare diseases of the central nervous system. The company's shares, focused on orphan diseases, exist in their own market space. Their price is determined by progress in clinical trials. There is virtually no connection to overall market trends, as the chart demonstrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cyclerion Therapeutics
Cyclerion Therapeutics, a biotech company focused on treating diseases of the central nervous system, is exhibiting the volatility typical of the sector. Its weekly share price performance is a direct reaction to the release of clinical trial data, which could dramatically change its valuation.
Weekly dynamics of market capitalization of the market segment - Neuro
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system. This is a high-risk business, and its stock price can soar or collapse following the publication of research data. The chart allows us to distinguish these unique events from the general movements in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cyclerion Therapeutics is a clinical-stage biotech company. Its future depends entirely on its success in developing CNS drugs. The chart shows that its stock moves solely on domestic news, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
CYCN - Market capitalization of the company Cyclerion Therapeutics
Cyclerion Therapeutics' market capitalization chart tells the story of its search for new applications for its scientific platform. Its dynamics reflect its shift from treating neurological diseases to other areas following clinical failures. Its low valuation reflects investors' assessment of its remaining assets and the likelihood of success for its new research programs.
CYCN - Share of the company's market capitalization Cyclerion Therapeutics within the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of serious CNS diseases. Its market share is small, reflecting its research-based nature. Its market capitalization is based on the assessment of its scientific platform and the potential of its candidate molecules in clinical trials.
Market capitalization of the market segment - Neuro
Below is a chart reflecting the combined weighting of the entire neurological pharmaceutical sector. For Cyclerion Therapeutics, which develops drugs for central nervous system disorders, this line represents a map of hope and risk. Its dynamics reflect the degree to which investors are willing to invest in one of the most complex and unpredictable areas of pharmaceuticals.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cyclerion Therapeutics develops drugs targeting the nitric oxide signaling pathway for the treatment of neurological diseases. Its market capitalization is a measure of its scientific approach. This is the market share of the overall market for fundamental research into signaling molecules.
Book value capitalization of the company, segment and market as a whole
CYCN - Book value capitalization of the company Cyclerion Therapeutics
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system. Its book value represents its financial resources for research. It consists of cash that allows the company to advance its developments through clinical trials. How has this research capital changed? The chart below shows.
CYCN - Share of the company's book capitalization Cyclerion Therapeutics within the market segment - Neuro
Cyclerion Therapeutics develops drugs for the treatment of central nervous system diseases. Its scientific work requires a resource base: a laboratory for studying sGC signaling pathways and developing new small molecules. The chart shows the company's share of the physical R&D infrastructure necessary for innovation in neuroscience.
Market segment balance sheet capitalization - Neuro
Cyclerion is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Cyclerion focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Cyclerion's assets are not factories, but a scientific platform and capital for developing drugs targeting the nitric oxide signaling pathway for the treatment of serious diseases of the central nervous system. Its book value reflects its financial resources for research. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company focused on treating diseases of the central nervous system. Its market value is determined by its scientific platform. Investors are betting on its ability to develop new drugs for complex neurological conditions.
Market to book capitalization ratio in a market segment - Neuro
Cyclerion Therapeutics is a biotech company focused on treating CNS diseases. Its valuation on this chart reflects investors' faith in its scientific platform, despite past setbacks. This is a bet that its current developments will prove more successful.
Market to book capitalization ratio for the market as a whole
Cyclerion Therapeutics focuses on developing drugs to treat serious diseases of the central nervous system. The company's market value is determined by the progress of its clinical trials and the potential of its scientific discoveries. This chart shows how the market generally values research-stage biotech companies.
Debts of the company, segment and market as a whole
CYCN - Company debts Cyclerion Therapeutics
Cyclerion, a biopharmaceutical company focused on treating diseases of the central nervous system, funds its clinical programs through existing cash and raised capital. This chart reflects its "survival" financing strategy, aimed at bringing the most promising candidates to key decision points.
Market segment debts - Neuro
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing drugs that target the nitric oxide signaling pathway to treat central nervous system disorders. This chart shows how the company funds its research, a typical biotech model where capital is used to test hypotheses in clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cyclerion Therapeutics
Cyclerion Therapeutics develops drugs targeting the nitric oxide signaling pathway to treat serious diseases of the central nervous system. Clinical trials in this area are complex and expensive. This chart shows how the company uses debt to fund its research programs, reflecting the high risks in the biotech sector.
Market segment debt to market segment book capitalization - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. This chart shows how the company finances its complex clinical trials, comparing its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system. Biopharmaceutical research is a marathon, requiring enormous financial investments. How dependent is the company on debt financing? This chart, showing the overall level of debt in the economy, provides context for assessing its survival strategy.
P/E of the company, segment and market as a whole
P/E - Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs that target the nitric oxide signaling pathway to treat serious diseases. This chart shows how investors value its scientific platform after a series of clinical trial failures. The valuation reflects both the risks and potential of its developments.
P/E of the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company specializing in the development of drugs that target the nitric oxide (NO) signaling pathway to treat serious diseases of the central nervous system. This chart illustrates the average valuation in the neuroscience sector, where investors evaluate the potential of new molecular mechanisms to treat complex diseases.
P/E of the market as a whole
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing drugs that restore cognitive function in neurodegenerative diseases. This chart reflects investors' overall risk appetite. It helps understand whether CYCN's valuation is based on the potential of its scientific developments or whether it moves in line with overall sentiment in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. The company has refocused its efforts on its most promising pipelines. This chart reflects investor expectations regarding the success of its updated strategy and the clinical potential of its remaining pipeline.
%20P%2FE%20Cyclerion%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cyclerion-Therapeutics&v=1772650066936 "Chart of the company's future (projected) P/E Cyclerion Therapeutics")
Future (projected) P/E of the market segment - Neuro
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system. Its value is determined by the potential of its drugs. This figure shows the average profitability expectations for the sector. This allows us to assess how optimistic the market is about Cyclerion's scientific developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772650066937 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its value is based on the potential of its scientific developments. This overall risk appetite chart shows how willing investors are to invest in long-term, risky neuroscience projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650066938 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Being in the clinical stage, its financial metrics reflect research expenditures. This chart illustrates its investment in research aimed at developing new treatments for complex neurological conditions.
Profit of companies in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company focused on developing drugs that target the nitric oxide signaling pathway to treat serious diseases of the central nervous system. This chart shows overall profitability in the neuroscience sector, where the discovery and exploitation of new molecular mechanisms can lead to breakthrough therapies.
Overall market profit
Cyclerion Therapeutics is a biopharmaceutical company developing treatments for diseases of the central nervous system. Its success and value are determined by progress in clinical trials. This process is completely independent of macroeconomic trends, as this chart shows, as the need for treatments for these diseases is high.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Future profits depend on progress in clinical trials and the ability to find commercialization partners. This chart reflects analysts' speculative expectations for its research and development pipeline.
%20profit%20of%20the%20company%20Cyclerion%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cyclerion-Therapeutics&v=1772650066980 "Graph of future (projected) profit of the company Cyclerion Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its approach is based on modulating the nitric oxide signaling pathway. The company's success depends on clinical data. This chart shows revenue projections for the neuroscience segment of the pharmaceutical company, providing context for evaluating Cyclerion's scientific approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772650066981 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650066982 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company focused on treating serious diseases of the central nervous system. There are no revenues at the clinical stage. This chart is a barometer of investor sentiment regarding its scientific developments. Its dynamics depend entirely on the results of clinical trials.
P/S market segment - Neuro
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious diseases of the central nervous system. The company leverages its expertise in nitric oxide signaling pathways to develop new drugs. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Cyclerion's developments.
P/S of the market as a whole
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. This chart highlights that for clinical-stage companies like Cyclerion, traditional revenue metrics are not applicable, and their value is determined solely by the potential of their research.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company focused on developing treatments for serious diseases of the central nervous system. The company's clinical-stage revenue estimates reflect investor confidence. This chart shows the market's confidence in Cyclerion's scientific approach and the commercial potential of its neuroscience drug candidates.
%20P%2FS%20Cyclerion%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cyclerion-Therapeutics&v=1772650066996 "The graph of the company's future (projected) P/S Cyclerion Therapeutics")
Future (projected) P/S of the market segment - Neuro
Cyclerion Therapeutics develops drugs targeting the nitric oxide signaling pathway to treat serious diseases of the central nervous system. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the scientific potential of its platform and the prospects of its drug candidates in clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772650066997 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system (CNS). The company shifted focus after a series of setbacks, as is typical for biotech. This chart of overall market expectations reflects investors' complex views on the high-risk CNS drug development sector, where the potential rewards are enormous.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650066999 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cyclerion Therapeutics
This metric reflects the financial health of Cyclerion Therapeutics, a clinical-stage biopharmaceutical company. The company develops drugs for the treatment of serious diseases of the central nervous system. It has no commercial sales revenue, and may generate income from partnerships or asset sales.
Sales of companies in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs for the treatment of serious diseases of the central nervous system. Following a strategic restructuring, the company is focused on advancing its candidates through clinical trials. Its future revenue structure will depend on the successful partnership or commercialization of these assets.
Overall market sales
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its prospects depend entirely on the success of its clinical programs. This overall economic activity chart is not relevant for valuing a company whose value is created in scientific laboratories, not in the consumer market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. The company is in the clinical stage, and its future revenue depends on the success of its research. This chart illustrates analyst expectations for the potential commercial success of its developments if approved.
%20sales%20of%20the%20company%20Cyclerion%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cyclerion-Therapeutics&v=1772650067027 "Schedule of future (projected) sales of the company Cyclerion Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Cyclerion Therapeutics develops drugs to treat serious diseases of the central nervous system (CNS). This chart shows the sales forecast for the neurological drug market. Is there a significant unmet need for new treatments that will drive market growth? This sets the overall backdrop for Cyclerion.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772650067028 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its value and prospects depend on scientific advances and clinical trial data. The general economic trends reflected in this chart do not directly impact its core business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650067041 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cyclerion Therapeutics
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. This chart reflects its financial position after shifting its strategy and focusing on new programs. Profitability is a future goal, dependent on the success of its ongoing clinical trials in neuroscience.
Market segment marginality - Neuro
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of serious diseases of the central nervous system. This chart reflects its current financial position, with profitability entirely dependent on future success in clinical trials, partnerships, and the commercialization of its research.
Market marginality as a whole
Cyclerion Therapeutics is a biotech company developing drugs to treat serious diseases of the central nervous system. Its future depends entirely on the results of clinical trials. This gross profitability chart reflects investors' willingness to fund capital-intensive research in one of the riskiest areas of pharmaceuticals.
Employees in the company, segment and market as a whole
Number of employees in the company Cyclerion Therapeutics
Cyclerion Therapeutics is a biotech company developing drugs to treat serious diseases of the central nervous system. Following a restructuring and shift in focus, the company's workforce dynamics are critical. This chart shows how the company has optimized its team to focus all resources on its most promising clinical programs.
Share of the company's employees Cyclerion Therapeutics within the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its team consists of scientists and clinicians conducting research and trials. This chart shows the company's share of the biotech labor market, reflecting its focus on R&D and the scale of its neuroscience research programs.
Number of employees in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company developing drugs that target the nitric oxide signaling pathway to treat diseases of the central nervous system. This chart shows its work in the neuroscience sector. Cyclerion's approach is aimed at restoring cognitive function, which has potential applications in a variety of diseases.
Number of employees in the market as a whole
Cyclerion Therapeutics is a biopharmaceutical company focused on treating serious diseases of the central nervous system. Its trajectory is marked by a long cycle of research and development. Unlike the general labor market dynamics shown in this graph, employment at Cyclerion is driven by scientific milestones and capital raising, rather than short-term economic factors.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics is a biotech company specializing in the treatment of central nervous system (CNS) diseases. Their value is their research portfolio. This chart shows how the market values their pipeline. It reflects the market value per scientist, which is a direct indicator of investor confidence in their future drugs.
%20of%20the%20company%20Cyclerion%20Therapeutics%20(CYCN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cyclerion-Therapeutics-CYCN&v=1772650067068 "Chart of market capitalization per employee (in thousands of dollars) of the company Cyclerion Therapeutics (CYCN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cyclerion Therapeutics (CYCN) develops drugs to treat serious diseases of the central nervous system. In biopharma, this chart is a barometer of faith in the company's science. A high market capitalization per employee, even without revenue, signals that investors highly value the potential of its scientific discoveries and patent portfolio.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772650067091 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cyclerion Therapeutics is a biopharmaceutical company developing drugs to treat serious diseases of the central nervous system. Its value is determined by its scientific pipeline. The chart shows a high valuation per employee, which is typical for clinical biotechs, where market capitalization reflects investor confidence in the future success of their developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650067093 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cyclerion Therapeutics (CYCN)
Cyclerion is a clinical-stage biotech company working in neurological diseases. Like most R&D companies, this chart likely shows the company's loss per employee. It reflects how much the company invests in each scientist and physician to conduct clinical trials and develop new molecules.
%20Chart%20Cyclerion%20Therapeutics%20(CYCN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cyclerion-Therapeutics-CYCN&v=1772650067094 "Company Profit Per Employee (in thousands of dollars) Chart Cyclerion Therapeutics (CYCN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company focused on treating serious diseases of the central nervous system. In this field, team performance is determined by the ability to advance complex drugs through clinical trials. This chart shows the financial return per employee, which is an indicator of the potential commercial success of their developments.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772650067096 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cyclerion Therapeutics is a biotech company focused on CNS diseases. Like many in this sector, they are in the R&D stage, staffed by scientists and primarily focused on clinical trials. This chart, showing the average market return per employee, helps us understand how the R&D model, based on investment in science, differs from the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650067110 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. During the clinical trials phase, revenue per employee may be nonexistent. This graph represents a future estimate: a successful drug could generate significant revenue, dramatically increasing this figure.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cyclerion-Therapeutics-CYCN&v=1772650067153 "Sales chart per company employee Cyclerion Therapeutics (CYCN)")
Sales per employee in the market segment - Neuro
Cyclerion Therapeutics is a clinical-stage biotech developing drugs for the treatment of rare CNS diseases. They have no commercial revenue. This chart, showing the average burn rate for the sector, serves as a benchmark for CYCN's R&D staffing efficiency compared to other neuroscience biotechs.
Sales per employee for the market as a whole
Cyclerion Therapeutics is a biotech company developing drugs to treat serious neurological diseases. Like many clinical-stage companies, their primary focus is R&D. This chart reflects their current status: the company is investing in research and does not yet have a commercial product on the market.
Short shares by company, segment and market as a whole
Shares shorted by company Cyclerion Therapeutics (CYCN)
Cyclerion (CYCN) is a biotech company focused on treating neurological diseases of the central nervous system. The company has previously suffered several failures in trials. This chart shows the number of short positions. These bears are betting that the company's new drug development efforts will also fail, which is typical for this complex sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cyclerion-Therapeutics-CYCN&v=1772650067256 "Short Shares Chart for the Company Cyclerion Therapeutics (CYCN)")
Shares shorted by market segment - Neuro
Cyclerion Therapeutics (CYCN) is a biotech company developing drugs that target the nitric oxide (NO) signaling pathway for the treatment of neurological diseases. This chart aggregates short positions in the neuroscience biotech sector. It reflects the high level of risk and investor skepticism regarding the complexity of development.
Shares shorted by the overall market
Cyclerion (CYCN) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing CYCN won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics (CYCN) develops drugs to treat serious diseases of the central nervous system (CNS). Following setbacks, the company is restructuring. This oscillator measures the strength of speculative moves. It shows when brief surges of hope (above 70) or deep disappointment (below 30) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cyclerion-Therapeutics-CYCN&v=1772650067284 "RSI 14 indicator chart for the company's stock Cyclerion Therapeutics (CYCN)")
RSI 14 Market Segment - Neuro
Cyclerion Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system (CNS) diseases. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to CYCN news from general euphoria or panic across this complex industry.
RSI 14 for the overall market
Cyclerion (CYCN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYCN (Cyclerion Therapeutics)
Cyclerion Therapeutics is a biopharmaceutical company focused on developing sGC stimulators, a new class of drugs for the treatment of severe neurological diseases. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their confidence in the success of this R&D platform and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYCN-Cyclerion-Therapeutics&v=1772650067320 "A chart showing analyst consensus forecasts for the expected stock price. CYCN (Cyclerion Therapeutics)")
The difference between the consensus estimate and the actual stock price CYCN (Cyclerion Therapeutics)
Cyclerion is a biotech company developing drugs to treat severe CNS diseases by targeting the sGC signaling pathway. This chart shows analysts' forecasts for the stock's upside and downside potential. It measures the gap between the price and forecast, reflecting their view of the company's scientific R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYCN-Cyclerion-Therapeutics&v=1772650067344 "A chart showing the difference between the consensus forecast and the actual stock price. CYCN (Cyclerion Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cyclerion (CYCN) is an early-stage biotech developing drugs to treat rare CNS diseases. This is a speculative R&D company. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in brain disease treatments are possible or whether they expect a "winter" in biotech funding.
Analysts' consensus forecast for the overall market share price
Cyclerion Therapeutics is a biotechnology company specializing in developing drugs for the treatment of rare CNS (central nervous system) diseases. This chart reflects the overall market "risk appetite." For Cyclerion, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cyclerion Therapeutics
Cyclerion is a biotech R&D company focused on the sGC signaling pathway. They are developing small molecules (tablets) for the treatment of rare, severe CNS (neurological) diseases. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline, their clinical trial data, and their chances of success.
AKIMA Market Segment Index - Neuro
Cyclerion Therapeutics (CYCN) is a biopharmaceutical company specializing in CNS diseases. They are developing small-molecule stimulators of sGC, a key enzyme they believe could help treat neurological and cognitive disorders. The chart shows the segment's average index, helping investors assess how CYCN's risks in this complex field compare to the average.
The AKIM Index for the overall market
Cyclerion Therapeutics is a biotech company focused on developing drugs for the treatment of mitochondrial and central nervous system diseases. It is a spinoff of Ironwood. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, which is restructuring its strategy, stacks up against overall economic trends.
